The world is facing up the most considerable vaccination effort in history to end the
Coronavirus disease 2019 (COVID-19) pandemic. Several monoclonal antibodies (mAbs) …

Several neutralizing monoclonal antibodies (mAbs) to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) have been developed and are now under evaluation in clinical …

Monoclonal antibodies (mAbs) have been known since the 1970s. However, their
therapeutic potential in the medical field has recently emerged, with the advancement of …

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and
limited vaccine availability for the general population in most countries, the monoclonal …

Introduction Anti-spike monoclonal antibodies (mAbs) were previously authorized for the
prevention and treatment of COVID-19 in immunocompromised patients. However, they are …

The rapid emergence of Coronavirus disease-2019 (COVID-19) caused by severe acute
respiratory syndrome 2 coronavirus (SARS-CoV-2) as a pandemic that presents an urgent …

One of the major breakthroughs to combat the current Coronavirus Disease 2019 (COVID-
19) pandemic has been the development of highly effective vaccines against the Severe …

Major efforts have been made in the search for effective treatments since the outbreak of the
COVID-19 infection in December 2019. Extensive research has been conducted on drugs …

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of
SARS-CoV-2 variants raised concerns about these therapies' efficacy and long-term …

Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …